# CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients

> **NCT03732430** · PHASE2 · UNKNOWN · sponsor: **Taizhou Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Thoracic Malignancies

## Interventions

- **DRUG:** IBI308

## Key facts

- **NCT ID:** NCT03732430
- **Lead sponsor:** Taizhou Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-14
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03732430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03732430, "CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03732430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*